0549: Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis

Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain

Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).

Methods: Retrospective observational study of RA patients, fulfilling the ACR/EULAR 2010 classification criteria, vaccinated against the SARS-CoV-2 virus from December 2020 to October 2021, who had post-vaccination serology and subsequent follow-up for a minimum of 6 months in a university hospital. The efficacy and effectiveness of the vaccine was evaluated by analyzing the serological response (anti-SARS-CoV-2 IgG antibodies) and the incidence of post-vaccination SARS-CoV-2 infection. Vaccine safety was investigated recording adverse events and RA flares. Logistic and linear multivariate regression analyzes adjusted for age, sex, and time elapsed from vaccination to serological determination were used to identify factors associated with vaccine response. Statistical analysis was carried out with Stata® and significance was set at p< 0.05.

Results: We included 118 patients with RA (87.2% women, mean age 65.4±11.6 years, mean evolution 12.0±9.6 years) vaccinated against SARS-CoV-2 (95.76% received the complete vaccination schedule). Patient characteristics are shown in Table 1 and Table 2 and types of vaccines and schedule are shown in Image 1. Most patients (88.1%) developed humoral immunogenicity. Univariate analysis of factors associates with humoral response and grade of response to the vaccine are shown in Table 1 and Table 2. Multivariate analysis found that smoking (OR 0.96, 95%CI: 0.94-0.99, p=0.034) was the only variable significantly associated with humoral response to the vaccine. The degree of serological response was significantly related to younger age (coefficient -16.11, 95%CI: -31.84 to -0.39, p=0.045) and previous COVID-19 infection (coefficient 4.496, IC 95%: 3.604-5.388, p< 0.001), which had occurred in 17.8% (5% severe) and was associated with male gender (p=0.016). After vaccination, 18.6% presented SARS-CoV-2 infection, although mild. Vaccine adverse events (19.5%) were mostly mild and associated with age (OR 0.95, 95%CI: 0.91–0.99, p=0.042). RA flares were anecdotal (1.7%), being inversely related to age (OR 0.95, 95%CI: 0.91-0.99, p=0.042).

Conclusion: Our results, with a limited sample, suggest that the SARS-CoV-2 vaccine induces adequate humoral immunogenicity, with an acceptable safety profile in RA patients, reducing the severity of SARS-CoV-2 infection.
Table 1. Population characteristics and univariate analysis of its association with response and grade of response to SARS-CoV-2 vaccine.

Table 2. Treatment characteristics of our population and univariate analysis of its association with response and grade of response to SARS-CoV-2 vaccine.

Image 1. Type of SARS-CoV-2 vaccine used and safety profile.
Disclosures: E. Vicente-Rabaneda, None; M. Torres, None; M. Uriarte, None; P. Quiroga-Colina, None; A. Gutiérrez, None; A. Triguero, None; F. Gutiérrez, None; N. García, None; A. Romero-Robles, None; L. Cardeñoso, None; S. Castañeda, Roche.